<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654381</url>
  </required_header>
  <id_info>
    <org_study_id>1218.23</org_study_id>
    <nct_id>NCT00654381</nct_id>
  </id_info>
  <brief_title>Japanese P III vs Voglibose and Placebo</brief_title>
  <official_title>A Double-blind Phase III Study to Evaluate the Efficacy of BI 1356 5 mg and 10 mg vs. Placebo for 12 Weeks and vs. Voglibose 0.6 mg for 26 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control, Followed by an Extension Study to 52 Weeks to Evaluate Long-term Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the efficacy, safety and tolerability of
      Linagliptin (BI 1356) (5 mg or 10 mg / once daily) compared to placebo given for 12 weeks and
      voglibose for 26 weeks as mono therapy in patients with type 2 diabetes mellitus with
      insufficient glycaemic control. Furthermore, long-term safety is evaluated with an extension
      treatment to 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c at Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examination of Long-term Safety of Linagliptin (52-week Treatment)</measure>
    <time_frame>52 weeks</time_frame>
    <description>The incidence of AEs (Preferred Terms) with a frequency of 5% or more in the patients with type 2 diabetes mellitus who received linagliptin (5 mg or 10 mg) once daily for 52 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Efficacy Response of HbA1c at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Efficacy Response of HbA1c at Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Efficacy Response of HbA1c at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">561</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>voglibose 0.2 mg three times a day (TID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1356 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1356 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356</intervention_name>
    <description>5 mg/daily</description>
    <arm_group_label>BI 1356 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356</intervention_name>
    <description>10 mg/daily</description>
    <arm_group_label>BI 1356 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voglibose placebo</intervention_name>
    <description>three times daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356 placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voglibose</intervention_name>
    <description>0.6 mg/daily</description>
    <arm_group_label>voglibose 0.2 mg three times a day (TID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Japanese patients with a diagnosis of type 2 diabetes mellitus. Antidiabetic therapy
             has to be stable for at least 10 weeks before Visit 1.

          2. Glycosylated haemoglobin A1 (HbA1c) 7.0 - 10.0% at Visit 3 (beginning of the 2-week
             placebo run-in phase)

          3. Age: &gt;= 20 and &lt;= 80

          4. Body Mass Index (BMI) &lt;= 40 kg/m2

        Exclusion criteria:

          1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months
             before Visit 1

          2. Impaired hepatic function

          3. History of severe allergy/hypersensitivity

          4. Treatment with anti-diabetic, anti obesity drugs, etc 3 months before Visit 1

          5. Fasting blood glucose &gt;240 mg/dl (=13.3 mmol/L) at Visits 2 or 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.23.05 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asahi, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.06 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Funabashi, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.21 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hitachinaka, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.44 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hitachiota, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.09 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Imizu, Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.45 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inashiki-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.13 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izumisano, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.27 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kariya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.47 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitakatsushika-gun, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.39 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitakyuushuu, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.02 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.03 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.10 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.37 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marugame, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.38 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marugame, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.23 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.07 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Meguro-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.25 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.26 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.28 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.29 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.30 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.04 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.15 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.34 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Sakai, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.22 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishishinjyuku, Shinjyuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.16 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oita, Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.40 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oita, Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.36 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.11 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.12 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.32 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.33 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.35 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.17 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.18 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.19 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.41 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.42 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.43 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.01 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.20 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.46 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.08 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjyuku-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.14 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.31 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takatsuki, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.23.48 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <results_first_submitted>May 18, 2011</results_first_submitted>
  <results_first_submitted_qc>July 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2011</results_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voglibose</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total 6 groups (including sub-groups in placebo and voglibose groups)</recruitment_details>
      <pre_assignment_details>Placebo group has 2 sub-groups, placebo-linagliptin 5mg (from 2nd stage) and placebo-linagliptin 10mg (from 2nd stage).
Both Linagliptin 5 mg and 10 mg groups don't have sub-group. Voglibose group has 2 sub-groups, voglibose-linagliptin 5mg (from 3rd stage) and voglibose-linagliptin 10mg (from 3rd stage).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo - BI1356 (Linagliptin) 5mg - Linagliptin 5mg</title>
          <description>Placebo in Stage 1 - 5 mg in Stage 2 - 5 mg in Stage 3</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Linagliptin 5mg - Linagliptin 10mg</title>
          <description>Placebo in Stage 1 - 10 mg in Stage 2 - 10 mg in Stage 3</description>
        </group>
        <group group_id="P3">
          <title>Linagliptin 5mg - Linagliptin 5mg - Linagliptin 5mg</title>
          <description>5 mg in Stage 1 - 5 mg in Stage 2 - 5 mg in Stage 3</description>
        </group>
        <group group_id="P4">
          <title>Linagliptin 10 mg - Linagliptin 10 mg - Linagliptin 10 mg</title>
          <description>10 mg in Stage 1 - 10 mg in Stage 2 - 10 mg in Stage 3</description>
        </group>
        <group group_id="P5">
          <title>Voglibose - Voglibose - Linagliptin 5mg</title>
          <description>Voglibose in Stage 1 - Voglibose in Stage 2 - 5 mg in Stage 3</description>
        </group>
        <group group_id="P6">
          <title>Voglibose - Voglibose - Linagliptin 10mg</title>
          <description>Voglibose in Stage 1 - Voglibose in Stage 2 - 10 mg in Stage 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1st Stage</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="160"/>
                <participants group_id="P5" count="81"/>
                <participants group_id="P6" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="155"/>
                <participants group_id="P5" count="79"/>
                <participants group_id="P6" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>2nd Stage</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="155"/>
                <participants group_id="P5" count="79"/>
                <participants group_id="P6" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="151"/>
                <participants group_id="P5" count="71"/>
                <participants group_id="P6" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Stage</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="151"/>
                <participants group_id="P5" count="71"/>
                <participants group_id="P6" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="142"/>
                <participants group_id="P4" count="142"/>
                <participants group_id="P5" count="68"/>
                <participants group_id="P6" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Closure of the trial site</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>The patients with placebo at the start of randomised study medication</description>
        </group>
        <group group_id="B2">
          <title>Linagliptin 5mg</title>
          <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
        </group>
        <group group_id="B3">
          <title>Linagliptin 10 mg</title>
          <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
        </group>
        <group group_id="B4">
          <title>Voglibose</title>
          <description>The patients with voglibose at the start of randomised study medication</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="159"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="162"/>
            <count group_id="B5" value="561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="8.9"/>
                    <measurement group_id="B2" value="60.3" spread="9.4"/>
                    <measurement group_id="B3" value="61.3" spread="10"/>
                    <measurement group_id="B4" value="58.5" spread="9.9"/>
                    <measurement group_id="B5" value="60.0" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c at Week 12</title>
        <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
        <time_frame>12 weeks</time_frame>
        <population>For the 12-week analysis, it was planed the comparison between Linagliptin and placebo. Then the patients with voglibose were excluded in this analysis.Full analysis set for 12-week treatment period with Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The patients with placebo at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 10 mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 12</title>
          <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
          <population>For the 12-week analysis, it was planed the comparison between Linagliptin and placebo. Then the patients with voglibose were excluded in this analysis.Full analysis set for 12-week treatment period with Last Observation Carried Forward.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.08"/>
                    <measurement group_id="O2" value="-0.24" spread="0.06"/>
                    <measurement group_id="O3" value="-0.25" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5 mg vs placebo at week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment,baseline HbA1c, and number of previous antidiabetic medication</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 10 mg vs placebo at week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment,baseline HbA1c, and number of previous antidiabetic medication</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c at Week 26</title>
        <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
        <time_frame>26 weeks</time_frame>
        <population>For the 26-week analysis, it was planed the comparison between Linagliptin and Voglibose. Then the patients with placebo were excluded in this analysis.Full analysis set for 26-week treatment period with Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 10 mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O3">
            <title>Voglibose</title>
            <description>The patients with voglibose at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 26</title>
          <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
          <population>For the 26-week analysis, it was planed the comparison between Linagliptin and Voglibose. Then the patients with placebo were excluded in this analysis.Full analysis set for 26-week treatment period with Last Observation Carried Forward.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.07"/>
                    <measurement group_id="O2" value="-0.19" spread="0.07"/>
                    <measurement group_id="O3" value="0.19" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment,baseline HbA1c, and number of previous antidiabetic medication</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 10 mg vs voglibose at week 26</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment,baseline HbA1c, and number of previous antidiabetic medication</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Efficacy Response of HbA1c at Week 12</title>
        <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>For the 12-week analysis, it was planed the comparison between Linagliptin and placebo. Then the patients with voglibose were excluded in this analysis.Full analysis set for 12-week treatment period with Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The patients with placebo at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 10 mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Efficacy Response of HbA1c at Week 12</title>
          <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 12</description>
          <population>For the 12-week analysis, it was planed the comparison between Linagliptin and placebo. Then the patients with voglibose were excluded in this analysis.Full analysis set for 12-week treatment period with Last Observation Carried Forward.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c &lt;7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c reduction from baseline ≥0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Efficacy Response of HbA1c at Week 26</title>
        <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 26</description>
        <time_frame>26 weeks</time_frame>
        <population>For the 26-week analysis, it was planed the comparison between Linagliptin and Voglibose. Then the patients with placebo were excluded in this analysis.Full analysis set for 26-week treatment period with Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 10 mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O3">
            <title>Voglibose</title>
            <description>The patients with voglibose at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Efficacy Response of HbA1c at Week 26</title>
          <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 26</description>
          <population>For the 26-week analysis, it was planed the comparison between Linagliptin and Voglibose. Then the patients with placebo were excluded in this analysis.Full analysis set for 26-week treatment period with Last Observation Carried Forward.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c &lt;7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c reduction from baseline ≥0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Efficacy Response of HbA1c at Week 52</title>
        <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 52</description>
        <time_frame>52 weeks</time_frame>
        <population>For the 52-week analysis, it was planed to analyse for Linagliptin 5mg and 10mg. Then the patients with placebo and voglibose were excluded in this analysis. Full analysis set for 52-week treatment period with Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 10mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Efficacy Response of HbA1c at Week 52</title>
          <description>HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 52</description>
          <population>For the 52-week analysis, it was planed to analyse for Linagliptin 5mg and 10mg. Then the patients with placebo and voglibose were excluded in this analysis. Full analysis set for 52-week treatment period with Last Observation Carried Forward</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c &lt;7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c &lt;6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c reduction from baseline ≥0.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</title>
        <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
        <time_frame>12 weeks</time_frame>
        <population>For the 12-week analysis, it was planed the comparison between Linagliptin and placebo. Then the patients with voglibose were excluded in this analysis.Full analysis set for 12-week treatment period with Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The patients with placebo at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 10 mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</title>
          <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
          <population>For the 12-week analysis, it was planed the comparison between Linagliptin and placebo. Then the patients with voglibose were excluded in this analysis.Full analysis set for 12-week treatment period with Last Observation Carried Forward.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.5"/>
                    <measurement group_id="O2" value="-12.3" spread="1.9"/>
                    <measurement group_id="O3" value="-13.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5 mg vs placebo at week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment,baseline FPG, and number of previous antidiabetic medication</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-19.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.4</ci_lower_limit>
            <ci_upper_limit>-14.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 10 mg vs placebo at week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment,baseline FPG, and number of previous antidiabetic medication</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-20.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.2</ci_lower_limit>
            <ci_upper_limit>-14.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26</title>
        <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
        <time_frame>26 weeks</time_frame>
        <population>For the 26-week analysis, it was planed the comparison between Linagliptin and Voglibose. Then the patients with placebo were excluded in this analysis.Full analysis set for 26-week treatment period with Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 10 mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O3">
            <title>Voglibose</title>
            <description>The patients with voglibose at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26</title>
          <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
          <population>For the 26-week analysis, it was planed the comparison between Linagliptin and Voglibose. Then the patients with placebo were excluded in this analysis.Full analysis set for 26-week treatment period with Last Observation Carried Forward</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="2.4"/>
                    <measurement group_id="O2" value="-7.8" spread="2.4"/>
                    <measurement group_id="O3" value="2.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5 mg vs Voglibose at week 26</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0239</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment,baseline FPG, and number of previous antidiabetic medication</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-6.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.0</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 10 mg vs voglibose at week 26</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment,baseline FPG, and number of previous antidiabetic medication</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-9.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>-3.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52</title>
        <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
        <time_frame>52 weeks</time_frame>
        <population>The patients who had at least one available baseline FPG measurement under the treatment with linagliptin</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 10 mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52</title>
          <description>Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication</description>
          <population>The patients who had at least one available baseline FPG measurement under the treatment with linagliptin</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="2.7"/>
                    <measurement group_id="O2" value="-5.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Examination of Long-term Safety of Linagliptin (52-week Treatment)</title>
        <description>The incidence of AEs (Preferred Terms) with a frequency of 5% or more in the patients with type 2 diabetes mellitus who received linagliptin (5 mg or 10 mg) once daily for 52 weeks</description>
        <time_frame>52 weeks</time_frame>
        <population>The patients who received at least one dose of linagliptin 5 mg or linagliptin 10 mg during the randomised treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg</title>
            <description>The patients with linagliptin 5 mg at the start of randomised study medication</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 10 mg</title>
            <description>The patients with linagliptin 10 mg at the start of randomised study medication</description>
          </group>
        </group_list>
        <measure>
          <title>Examination of Long-term Safety of Linagliptin (52-week Treatment)</title>
          <description>The incidence of AEs (Preferred Terms) with a frequency of 5% or more in the patients with type 2 diabetes mellitus who received linagliptin (5 mg or 10 mg) once daily for 52 weeks</description>
          <population>The patients who received at least one dose of linagliptin 5 mg or linagliptin 10 mg during the randomised treatment period</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasopharyngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (1st Stage)</title>
        </group>
        <group group_id="E2">
          <title>Linagliptin 5mg (2nd-Extension Stage After Placebo)</title>
        </group>
        <group group_id="E3">
          <title>Linagliptin 10mg (2nd-Extension Stage After Placebo)</title>
        </group>
        <group group_id="E4">
          <title>Linagliptin 5mg (1st-2nd-Extension Stage)</title>
        </group>
        <group group_id="E5">
          <title>Linagliptin 10mg (1st-2nd-Extension Stage)</title>
        </group>
        <group group_id="E6">
          <title>Voglibose (1st-2nd Stage)</title>
        </group>
        <group group_id="E7">
          <title>Linagliptin 5mg (Extension Stage After Voglibose)</title>
        </group>
        <group group_id="E8">
          <title>Linagliptin 10mg (Extension Stage After Voglibose)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Airway burns</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Limb deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Gastric cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="107" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="83" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="31" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

